BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/23/2022 10:13:16 AM | Browse: 428 | Download: 982
 |
Received |
|
2022-03-09 12:11 |
|
Peer-Review Started |
|
2022-03-09 12:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-11 21:19 |
|
Revised |
|
2022-04-30 05:42 |
|
Second Decision |
|
2022-08-15 06:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-08-16 18:37 |
|
Articles in Press |
|
2022-08-16 18:37 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-09-07 12:58 |
|
Typeset the Manuscript |
|
2022-09-15 08:35 |
|
Publish the Manuscript Online |
|
2022-09-23 10:13 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Aswathy R Devan, Keechilat Pavithran, Bhagyalakshmi Nair, Maneesha Murali and Lekshmi R Nath |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Amrita Vishwa Vidyapeetham SEED grant |
K-PHAR-22-662 |
|
| Corresponding Author |
Lekshmi R Nath, PhD, Assistant Professor, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Ponekkara, Kochi 682041, Kerala, India. lekshmirnath@aims.amrita.edu |
| Key Words |
Transforming growth factor-beta 1; Inflammation; Immunosuppression; Fibrogenesis; Hepatocellular carcinoma; Biomarker; Immunotherapy |
| Core Tip |
Transforming growth factor-beta 1 (TGF-β1) exhibits a progressive elevation throughout hepatic dysfunction starting from hepatitis to hepatocellular carcinoma (HCC) as an inflammatory cytokine, pro-fibrogenic marker, immunosuppressive agent and pro-carcinogenic growth factor. Aberrant TGF-β1 activation in HCC is associated with poor prognosis and survival. TGF-β1 mediated immunosuppression disturbs the anticancer surveillance and the efficacy of the immunotherapeutic agent. This pleiotropic effect of TGF-β1 in the context of HCC makes it ideal as a diagnostic, prognostic, and therapeutic candidate in HCC. |
| Publish Date |
2022-09-23 10:13 |
| Citation |
Devan AR, Pavithran K, Nair B, Murali M, Nath LR. Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma. World J Gastroenterol 2022; 28(36): 5250-5264 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i36/5250.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i36.5250 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
